Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study

Not yet recruitingOBSERVATIONAL
Enrollment

75

Participants

Timeline

Start Date

October 1, 2023

Primary Completion Date

June 1, 2026

Study Completion Date

June 1, 2027

Conditions
Pathological Response Rate, Circulating Tumour DNA
Interventions
DIAGNOSTIC_TEST

MeD-seq

MeD-seq analyse: DNA treatment bisulfite --\> unmethylated C-nucleotide trabsformed in uracil.--\> PCR --\> next generation sequencing (NGS) --\> localization methylated nucleotides (enzym LpnPI).

Sponsors
All Listed Sponsors
lead

Erasmus Medical Center

OTHER

NCT06035471 - Can we Use a Simple Blood Test to Reduce Unnecessary Adverse Effects From Radiotherapy by Timely Identification of Radiotherapy-resistant Rectal Cancers? MeD-Seq Rectal Study | Biotech Hunter | Biotech Hunter